CVS Health Chief Executive Officer Karen Lynch has stepped down and will be replaced by David Joyner, who runs the company's pharmacy benefit firm, Caremark.

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price target was ...

TD Cowen analyst Charles Rhyee maintained a Buy rating on CVS Health (CVS – Research Report) today and set a price target of $85.00. The ...

CVS Health has a new CEO: David Joyner, a seasoned veteran in the healthcare industry, is stepping into the challenging role. He takes the helm during a turbulent period for CVS, as it grapples ...

The Caremark pharmacy benefits management business that Joyner led is under scrutiny from the Federal Trade Commission, which alleged CVS and its rivals drove up insulin prices. Congress is ...

CVS Health said Friday that it has replaced chief executive Karen Lynch, abruptly ending a turbulent tenure during which she struggled to knit together its retail pharmacies and other businesses ...

In September, the Federal Trade Commission took aim at big pharmacy benefits managers, including CVS subsidiary Caremark, accusing them of inflating insulin prices. “We are not surprised by the ...

Lynch will be replaced by CVS Caremark president David Joyner, who will attempt to steer the health care giant through a worsening environment of rising medical costs. CVS, which had cut its ...

The Caremark pharmacy benefits management business that Joyner led is under scrutiny from the Federal Trade Commission, which alleged CVS and its rivals drove up insulin prices. Congress is ...

Joyner, who served most recently as president of CVS Caremark, the company's pharmacy benefit management division, took the CEO role as of Oct. 17. He succeeds Karen Lynch, who "stepped down from ...